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ABSTRACT
Objectives: In general populations, the adverse effects
of smoking on coronary risk have been demonstrated to
be greater in women than in men; whether this is true
for individuals with diabetes is unclear.
Design: Cohort study.
Setting: 20 countries worldwide participating in the
ADVANCE (Action in Diabetes and Vascular Disease:
Preterax and Diamicron modified release Controlled
Evaluation) trial.
Participants: 11 140 patients with type 2 diabetes
aged ≥55 years and in cardiovascular risk at the time of
randomisation.
Primary and secondary outcome measures: Major
cardiovascular events (death from cardiovascular
disease, non-fatal stroke or non-fatal myocardial
infarction (MI)), all cardiovascular events (major
cardiovascular event or peripheral arterial disease or
transient ischaemic attack), and all-cause mortality.
Secondary outcome measures were major coronary
events (fatal and non-fatal MI), major cerebrovascular
events (fatal and non-fatal stroke), nephropathy (new or
worsening renal disease), and all cancer.
Results: At baseline, 6466 (56% women) participants
were never-smokers, 1550 (28% women) were daily
smokers and 3124 (21% women) were former smokers.
Median follow-up time was 5 years. In Cox regression
models after multiple adjustments, compared with never
smoking, daily smoking was associated with increased
risk of all primary and secondary outcomes with the
exception of major cerebrovascular disease. Only for
major coronary events was there any evidence of a
stronger effect in women than in men (ratio of the
adjusted HRs women:men; 1.64 (0.83 to 3.26) p=0.08).
For all other outcomes considered, the hazards of
smoking were similar in men and women. Quitting
smoking was associated with a 30% reduction in all-
cause mortality (p=0.001) in both sexes.
Conclusions: In individuals with diabetes, the effects
of smoking on all major forms of cardiovascular disease
are equally as hazardous in women and men with the
possible exception of major coronary events where
there was some evidence of a greater hazard in
women.
Trial registration number: NCT00145925.
Strengths and limitations of this study
▪ The ADVANCE (Action in Diabetes and Vascular
Disease: Preterax and Diamicron modified
release Controlled Evaluation) trial was a rando-
mised, factorial controlled trial conducted in 20
countries providing detailed and well-
documented data throughout the trial.
▪ This study includes a broad variety of cardiovas-
cular and other outcomes associated with
smoking that all have been adjudicated providing
solid evidence of the risks associated with
smoking.
▪ The issue of generalisability is a concern when
using data from a clinical trial to inform on risk
in the general population.
▪ There is a potential for misclassification of some
individuals who were ‘occasional’ smokers (ie,
not daily smokers) as never-smokers, resulting
in an attenuation of the strength of the associa-
tions between smoking and vascular outcomes.
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INTRODUCTION
In recent years, there has been a greater appreciation of
the possible existence of important and clinically mean-
ingful sex differences in the impact of risk factors on
selected health outcomes.1–3 Type 2 diabetes has
unequivocally been demonstrated to be a more potent
risk factor for coronary heart disease (CHD) and stroke
in women than in men.1 3 Similarly, cigarette smoking
has also been shown to confer an excess risk of CHD in
women than in men in otherwise healthy populations.
For example, compared with never-smokers, women who
smoke have a 25% greater relative risk of CHD than
men independent of sex differences in the levels of
other cardiovascular risk factors.2 4 Despite the almost
universal acceptance of cigarette smoking as a major
hazard for cardiovascular disease (CVD) in individuals
with and without diabetes, the prevalence of smoking in
those with diabetes (in whom the risk for CVD is already
substantially elevated), in the USA and the UK is high
and comparable to that of the general population at 20–
25%.5 6 According to a recent multicentre cohort study
in Europe, the current smoking prevalence among indi-
viduals with type 2 diabetes is similar to that of the
general population where current smokers are 25% vs
28% and never-smokers 39% vs 42%, respectively.7
In a recent meta-analysis that examined the effects of
smoking on vascular risk among individuals with type 1
and/or 2 diabetes, although not formally tested, there
was some evidence that women with diabetes who smoke
are at increased risk of CHD (but not other vascular out-
comes) compared with their male counterparts.8 Since
this subgroup analysis was based on data from only two
small studies, it precludes any deﬁnitive conclusions
being drawn about the sex-speciﬁc nature of the associ-
ation, and thus it remains to be determined whether
smoking exerts a differential effect on vascular outcomes
in women and men with diabetes.
In general populations, the adverse effects of smoking
on coronary risk have been demonstrated to be greater
in women than in men; whether this is true for indivi-
duals with diabetes is unclear. We sought to investigate
smoking-associated risks in men and women with type 2
diabetes from 20 countries worldwide participating in
the ADVANCE (Action in Diabetes and Vascular Disease:
Preterax and Diamicron modiﬁed release Controlled
Evaluation) trial.
METHODS
We analysed the 11 140 patients enrolled on the
ADVANCE study (ClinicalTrials.gov number
NCT00145925). The ADVANCE study was a randomised,
factorial, controlled trial conducted in 20 countries
including participants aged at least 55 years who had
been diagnosed with type 2 diabetes after the age of
30 years. All participants had a history of major macro-
vascular or microvascular disease or at least one add-
itional cardiovascular risk factor. The study consisted of
two treatment arms, one comparing intensive with stand-
ard glycaemic control and another comparing active
with standard antihypertensive treatment.
All analysed outcomes in the study were adjudicated.
The primary outcomes consisted of major cardiovascular
events (death from CVD, non-fatal stroke or non-fatal
myocardial infarction (MI)), all cardiovascular events
(major cardiovascular event or peripheral arterial
disease or transient ischaemic attack) and all-cause mor-
tality.9–11 The secondary outcomes comprised major cor-
onary events (fatal and non-fatal MI), major
cerebrovascular events (fatal and non-fatal stroke),
nephropathy (new or worsening renal disease) and all
cancer.9–11 Smoking was categorised, by self-report, into
three groups including daily smoking, former smoking
and never smoking. Daily smoking was deﬁned by daily
cigarette smoking (at least one). ‘Previous smoking of at
least one cigarette daily or nearly daily for at least a year’
was used to classify ‘former smoking’. Time since
smoking cessation in former smokers at randomisation
was recorded in years. Written informed consents were
obtained from all study participants. The study eligibility
criteria and study methods,9 as well as the main
results,10 11 have been published previously.
Statistical analyses
The main analyses included assessing daily smoking
versus never smoking and former smoking versus daily
smoking. Besides sex as the factor of interest, the HRs
from Cox models were adjusted for age, body mass
index, randomised treatment groups, glycated haemo-
globin, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, triglycerides, creatinine clear-
ance, systolic blood pressure (SBP), heart rate, duration
of diabetes, history of CVD, any blood pressure medica-
tion, any lipid-lowering medication and use of acetyl sali-
cylic acid or thienopyridines, exercise times per week
(minimum 15 min/time), habit of weekly use of alcohol
and higher education (age at the time of ﬁnishing
highest level of education >15 years). Interactions
between sex and smoking habit were tested for each
studied outcome, and the ratio of the HRs (women:
men) were calculated. Incidence rates per 1000 person
years for primary and secondary outcomes were calcu-
lated by sex and smoking status at baseline. Sensitivity
analyses were conducted comparing the outcomes in
former versus never-smokers and in those smokers who
had quit smoking more than 10 years and less than
10 years since study baseline. Analyses were performed
using SAS V.9.3 (SAS Institute Inc, Cary, North
Carolina).
RESULTS
At baseline, of the 11 140 study participants, 14% were
daily smokers (17% men and 9% women) and 28%
were former smokers (38% men and 14% women).
Table 1 describes the general characteristics of the study
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population by sex, whereas the corresponding ﬁgures of
the entire population have been published previously.12
Daily smokers were younger, which may account in part
for the shorter duration of diabetes and lower SBP in
this subgroup compared with the other two subgroups
(p<0.01 in all).
The median duration of follow-up was 5 years, during
which time 1147 (10%) participants experienced a major
cardiovascular event and 1031 (9%) patients died. From
the 11 140 participants in the ADVANCE study, 15 were
lost to follow-up. In the entire cohort, the risk for all-
cause mortality associated with daily smoking was
increased (HR 1.52, 95% CI 1.27 to 1.83, <0.0001), and
in the analyses by sex the risk was higher in women (men;
HR 1.45, 95% CI 1.18 to 1.80, p=0.0006, women; HR
1.78, 95% CI 1.23 to 2.59, p=0.0025). In the subgroup of
daily and never-smokers, major cardiovascular events
were experienced by 772 participants (57% men; 43%
women) and 664 patients (59% men; 41% women) died.
The corresponding numbers in former and daily smokers
were 526 (85% men; 15% women) and 513 patients
(84% men; 16% women), respectively. Detailed numbers
for each outcome are reported in ﬁgures 1 and 2.
Web table 1 shows the incidence rates for each
outcome by sex and smoking status; there are higher
incidence rates among former compared with daily
smokers in men and women, whereas never-smokers
tend to have lower incidences in studied outcomes with
the exception of major cerebrovascular events.
As shown in ﬁgure 2, cigarette smoking was associated
with a signiﬁcantly increased risk for all of the primary
and most of the secondary outcomes in individuals with
type 2 diabetes: the risk of all-cause mortality and all
cancer was increased by about 60% in smokers com-
pared with never-smokers. For all other outcomes,
smoking increased the relative risk by between one-
quarter to one-third compared with never-smokers.
There was no obvious association with major cerebrovas-
cular events (HR 1.04 (95% CI 0.77 to 1.41)). In the
analysis comparing the sex-speciﬁc HRs, the effects of
smoking were broadly comparable in women and men
for each of the outcomes with the exception of major
coronary events: compared with never-smokers, women
who smoked had an approximately 60% greater risk
(ratio of HRs 1.64 (95% CI 0.83 to 3.26; p=0.081) com-
pared with men in ﬁgure 1).
Smoking cessation was associated with a reduced risk
of all-cause mortality (HR 0.70 (95% CI 0.57 to 0.87) for
former vs daily smoking; p=0.0012) with non-signiﬁcant
reductions in all other outcomes (ﬁgure 3). The
improvements in outcomes associated with quitting were
consistent in women and men as shown in ﬁgure 4.
Compared with never-smokers, the effect of quitting
smoking on most outcomes diminished but did not fully
Table 1 Patient characteristics by smoking status: mean (SD) unless otherwise stated
Men Women
Never Daily Former Never Daily Former
Number of individuals 2825 1116 2466 3641 434 658
Age (years) 66.4 (6.1) 62.3 (5.9) 66.9 (6.5) 65.7 (6.2) 62.9 (5.8) 67.1 (6.7)
Body mass index (kg/m2) 27.3 (4.6) 27.7 (4.9) 28.9 (4.6) 28.2 (5.5) 29.8 (5.8) 31.3 (5.9)
Current weekly alcohol use (%) 32.3 46.4 55.4 9.0 20.0 27.1
History of macrovascular disease (%) 34.3 30.7 43.0 25.2 17.7 33.4
History of microvascular disease (%) 11.1 8.7 10.6 11.0 7.8 7.6
History of stroke (%) 11.1 8.0 8.8 9.2 4.6 7.4
Age at completion of highest level of
education (years)
20.0 (7.3) 19.3 (6.9) 18.7 (7.4) 17.1 (7.1) 17.6 (6.6) 17.3 (7.1)
Systolic blood pressure (mm Hg) 144.1 (20.8) 141.0 (20.8) 147.3 (21.0) 145.3 (2.2) 142.5 (20.9) 147.5 (22.9)
Diastolic blood pressure (mm Hg) 81.0 (11.0) 81.1 (10.9) 81.7 (10.7) 75.7 (11.5) 79.7 (11.0) 80.0 (11.3)
Heart rate (bpm) 74 (12) 75 (12) 72 (13) 76 (12) 75 (11) 74 (11)
Total cholesterol (mmol/L) 4.92 (1.14) 5.10 (1.10) 4.87 (1.05) 5.60 (1.22) 5.51 (1.23) 5.35 (1.17)
HDL cholesterol (mmol/L) 1.21 (0.34) 1.18 (0.30) 1.17 (0.31) 1.35 (0.37) 1.30 (0.37) 1.32 (0.36)
LDL cholesterol (mmol/L) 2.96 (0.96) 3.07 (1.02) 2.87 (0.98) 3.38 (1.05) 3.31 (1.09) 3.13 (1.03)
Triglycerides (mmol/L) 1.77 (1.21) 2.06 (1.30) 1.94 (1.29) 2.04 (1.33) 2.11 (1.30) 2.04 (1.23)
HbA1c (%) 7.45 (1.52) 7.67 (1.59) 7.35 (1.38) 7.65 (1.70) 7.45 (1.49) 7.40 (1.38)
Exercise times per week, (minimum
15 min/time)
9.0 (10.8) 9.3 (12.2) 8.6 (9.9) 9.0 (11.5) 7.8 (7.7) 7.5 (8.1)
Creatinine clearance (mL/min) 81.9 (27.0) 93.5 (30.3) 85.9 (28.2) 76.7 (28.3) 83.7 (27.2) 81.1 (28.3)
ACE/ARB medication (%) 46.7 43.7 54.2 43.6 50.2 55.2
β-blocker (%) 24.6 20.2 28.0 22.3 26.5 29.6
Any blood pressure medications (%) 74.8 67.3 75.3 77.0 72.4 80.2
Lipid-lowering medication (%) 32.0 36.0 45.5 27.4 41.7 49.5
Aspirin or thienopyridines (%) 48.8 47.9 54.7 39.7 40.1 49.8
Duration of diabetes (years) 8.6 (6.7) 6.4 (5.6) 7.9 (6.4) 8.2 (6.2) 6.4 (5.8) 7.2 (6.2)
ARB, angiotensin receptor blocker; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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negate the risks associated with past smoking habits (see
web table 2). The beneﬁts of quitting smoking, however,
were, in general, greater in those individuals who had
quit smoking for more than 10 years since study enrol-
ment than in those who had quit less than 10 years
before study initiation (see web table 3).
DISCUSSION
In this trial population of more than 11 000 patients
with type 2 diabetes, cigarette smoking was associated
with a signiﬁcantly increased risk of all cancer, CVD and
all-cause mortality, consistent with what we know about
the harms of prolonged smoking from observational
studies. Importantly, in this population, which is already
at substantially greater risk of premature mortality,
smoking cessation was associated with a signiﬁcant 30%
reduction in all-cause mortality. The hazards of smoking,
and conversely the beneﬁts of smoking cessation, were
broadly comparable in women and men, with the pos-
sible exception of major coronary events where there
was some suggestion of a greater adverse effect of
smoking in women compared with men. With respect to
all other outcomes, the effects of quitting smoking in
comparison to daily smoking were less pronounced; this
may have been due to a relatively short period of
follow-up combined with a lack of efﬁcacy of smoking
cessation (subsequent to a history of prolonged
smoking) to negate the risk for some of the outcomes
(especially cancer) under investigation. There was,
however, some evidence that the longer the period of
smoking cessation prior to study baseline, the greater
the beneﬁts (>10 years), a ﬁnding consistent with the lit-
erature. Alternatively, since a higher proportion of
former (43% in men and 33% in women) compared
Figure 1 HR and 95% CIs for daily smoking versus never smoking. The total number of individuals is 8016. Cox models
adjusted for age, sex, body mass index, randomised treatment groups, glycated haemoglobin, high-density lipoprotein
cholesterol, low-density lipoprotein cholesterol, triglycerides, creatinine clearance, systolic blood pressure, heart rate, duration of
diabetes, history of cardiovascular disease, any blood pressure medication, any lipid-lowering medication, use of acetyl salicylic
acid or thienopyridines, exercise times per week, alcohol use and level of education.
Figure 2 Ratio of the HRs (women:men) for daily smoking versus never smoking. *Total number of women is 4075 and men is
3941. Cox model adjustments are as in figure 1.
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with daily smokers (31% in men and 20% in women)
already had a history of macrovascular disease (which
may have been the reason for quitting) at baseline,
former smokers would therefore have had an increased
susceptibility towards an adverse CVD outcome com-
pared with daily smokers, a risk that is not sufﬁciently
ameliorated by quitting smoking.
Previously, a large-scale meta-analysis of 75 cohort
studies combining information on more than 4 million
individuals (predominantly free from CVD at study base-
line) and more than 67 000 CHD events suggested that
the coronary hazards of smoking are stronger in women
than in men, even after consideration of sex differences
in other major cardiovascular risk factors that may con-
found the association.2 Similarly, in the current study, on
the basis of about 400 coronary events, there was some
weak evidence that among individuals with diabetes, the
effects of smoking on coronary outcomes are more haz-
ardous in women than in men, although the test for
interaction was of borderline statistical signiﬁcance
(p=0.081). The potential mechanism responsible for the
greater adverse effects of smoking on CHD risk in
women than in men remains speculative. Historically,
women have been more likely to be undertreated with
respect to their cardiovascular risk, but more contem-
porary studies have indicated that the sex disparity in
treatment is diminishing. Since all of the participants in
this study were recruited into the ADVANCE trial,
women and men were treated and monitored according
to the trial protocol. We therefore consider it unlikely
that women were undertreated relative to men. Rather,
the tendency for women who smoke to be at greater cor-
onary hazard compared with men may be due to behav-
ioural or physiological sex differences in smokers; for
Figure 3 HR and 95% CIs for former versus daily smoking. The total number of individuals is 4674. Cox model adjustments are
as in figure 1.
Figure 4 Ratio of the HRs (women:men) for former versus daily smoking. *Total number of women is 1092 and men is 3582.
Cox model adjustments are as in figure 1.
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example, absorption of nicotine has been reported to be
greater among women than men.13
For major cerebrovascular disease, there was no evi-
dence of a sex difference in the impact of smoking on
subsequent cerebrovascular risk, which again is consist-
ent with ﬁndings from a large meta-analysis.4 The lack
of any clear evidence of a sex difference in
smoking-related risk of stroke (in contrast to CHD) is an
interesting ﬁnding, which potentially suggests that the
sex difference in smoking-related risk of CHD is unlikely
to be mediated by differences in smoking-related behav-
iour (such as a greater degree of smoke inhalation by
women) because the sex effect would also be shown for
stroke. Instead, it is plausible that some of the pathways
mediating the relationship between smoking and coron-
ary risk are more susceptible to the antioestrogenic
effect of smoking than those governing the relationship
between smoking and stroke risk. For example, reduced
oestrogen levels in smokers are considered to impact
negatively on components of the lipid proﬁle (a major
risk factor for CHD and, to a lesser extent, for stroke)
causing elevations in total cholesterol and triglycerides
while lowering levels of high-density lipoprotein
cholesterol.14
The lack of power to reliably examine sex differences
in the effects of smoking is a limitation of this study; spe-
ciﬁcally, the proportion of women who were current and
former smokers was substantially less than in men, which
is likely to have limited the ability to detect sex-speciﬁc
effects and any small but real sex differences in the asso-
ciations between smoking and outcomes. However, to
the best of our knowledge, this is the ﬁrst study in a trial
population of individuals with diabetes that has explored
the sex-speciﬁc effects of smoking on major disease out-
comes. The issue of generalisability is also a concern
when using data from a clinical trial to inform on risk in
the general population. We further acknowledge the
potential for misclassiﬁcation of some individuals who
were ‘occasional’ smokers (ie, not daily smokers) as
never-smokers resulting in an attenuation of the strength
of the associations between smoking and vascular out-
comes. However, this limitation is also true of the vast
majority of previous studies that have reported on the
sex-speciﬁc association between smoking and health out-
comes. Most studies largely deﬁned smoking in one of
two ways: smoking (yes/no) or as current, never and
former, either of which have the potential for misclassiﬁ-
cation of an individual’s smoking status at baseline as
well as during follow-up.2 Similarly, a lack of information
of change in smoking status over the duration of the
trial may have resulted in some former smokers being
misclassiﬁed as current smokers, which would be
expected to diminish the effects of smoking on out-
comes. However, in both instances, any misclassiﬁcation
is likely to have been non-differential between women
and men, and thus the validity of the internal sex com-
parisons is unlikely to have been materially affected.
There was also no information on smoking intensity,
which is likely to have been higher in men than in
women. Moreover, these current data are not without
precedent and are in agreement with a subgroup ana-
lysis of a meta-analysis that showed a greater adverse
effect for CHD due to smoking among women with dia-
betes compared with men.8
In summary, the effects of smoking and quitting are
broadly consistent between the sexes, although the possi-
bility of a greater adverse effect of smoking on coronary
outcomes in women as compared with men could not
be precluded.
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